{
    "Trade/Device Name(s)": [
        "BD Phoenix\u2122M Automated Microbiology System",
        "BD Phoenix\u2122 Automated Microbiology System Cefepime (0.5-64 \u03bcg/mL) Gram-Negative ID/AST or AST"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K063301",
    "Predicate Device Reference 510(k) Number(s)": [
        "N50510",
        "K020321",
        "K020323",
        "K020322",
        "K032675",
        "K060444"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "December 8, 2006",
    "Summary Letter Received Date": "November 1, 2006",
    "Submission Date": "October 31, 2006",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Cefepime"
    ],
    "Specimen Type(s)": [
        "Pure culture isolates of Gram-negative aerobic and facultative anaerobic bacteria",
        "Gram-positive bacteria isolates from pure culture"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix instrument",
        "BD Phoenix panels"
    ],
    "Method(s)/Technology(ies)": [
        "Broth-based microdilution",
        "Redox indicator detection"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing",
        "Minimum inhibitory concentration determination"
    ],
    "Submission Type(s)": [
        "System",
        "Panel",
        "Reagent",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix Automated Microbiology System for in vitro susceptibility testing of bacteria using cefepime (0.5-64 \u03bcg/mL) in Gram-negative ID/AST or AST panels",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria and most Gram-positive bacteria isolates, including use of cefepime (0.5-64 \u03bcg/mL) with removal of limitations for Proteus species",
    "fda_folder": "Microbiology"
}